Trioar
TRIOAR is a biotechnology company specializing in next-generation antibody-based therapeutics. They develop innovative platform technologies to improve the efficacy and safety of antibody-drug conjugates (ADCs) and immuno-oncology (IO) treatments, aiming to create better, safer, and more effective therapies for patients worldwide.
Industries
Nr. of Employees
small (1-50)
Patents
Compound comprising self-immolative group and ligand-drug conjugate comprising same
US-12576156-B2
View Details
Compound comprising self-immolative group and ligand-drug conjugate comprising same
US-12576156-B2
View DetailsProducts
Dual-function targeting domain platform (delivery + masking)
A targeting-domain platform designed to guide enhanced drug delivery to tumors while providing masking functionality to reduce off-target effects and toxicity.
Novel linker–payload platform
Linker–payload platform emphasizing stability, hydrophilicity, payload compatibility, and improved pharmacological properties for conjugated therapeutics.
Linker–toxin conjugation system for rapid tumor cell killing
Conjugation system combining linkers and cytotoxic payloads intended to rapidly induce tumor cell death while maintaining drug stability and efficacy.
Immuno-oncology therapeutic programs
Development programs focused on immune-based therapies that enhance patient immune responses against tumors.
Dual-function targeting domain platform (delivery + masking)
A targeting-domain platform designed to guide enhanced drug delivery to tumors while providing masking functionality to reduce off-target effects and toxicity.
Novel linker–payload platform
Linker–payload platform emphasizing stability, hydrophilicity, payload compatibility, and improved pharmacological properties for conjugated therapeutics.
Linker–toxin conjugation system for rapid tumor cell killing
Conjugation system combining linkers and cytotoxic payloads intended to rapidly induce tumor cell death while maintaining drug stability and efficacy.
Immuno-oncology therapeutic programs
Development programs focused on immune-based therapies that enhance patient immune responses against tumors.
Services
Joint R&D and collaboration services to accelerate preclinical development of antibody-based therapeutics using internal platforms and external expert networks.
Commercial collaborations and partnership arrangements leveraging proprietary antibody-platform technologies for therapeutic development.
Joint R&D and collaboration services to accelerate preclinical development of antibody-based therapeutics using internal platforms and external expert networks.
Commercial collaborations and partnership arrangements leveraging proprietary antibody-platform technologies for therapeutic development.
Expertise Areas
- Antibody-drug conjugates (ADCs)
- Linker–payload and conjugation chemistry
- Antibody engineering for tumor targeting
- Immuno-oncology therapeutics
Key Technologies
- Antibody-drug conjugates (ADCs)
- Linker–payload chemistry
- Linker–toxin systems
- Dual-function targeting domains (delivery + masking)
News & Updates
Announcement of third-party allocation of paid-in capital increase and new stock issuance on March 18, 2025.
Daejeon City actively promotes the 3rd D-Unicorn Project as of May 15, 2024.
TRIOAR was selected as the winner of the Seoul-BMS Innovation Square Challenge in 2023, announced on November 23, 2023.
The Small and Medium Business Administration selected 51 baby unicorn companies, providing up to 17.3 billion KRW support, announced on May 30, 2023.
TRIOAR, which possesses an ADC platform, attracted 12 billion KRW in Series A investment on May 25, 2023.
Announcement of third-party allocation of paid-in capital increase and new stock issuance on May 8, 2023.
Announcement of third-party allocation of paid-in capital increase and new stock issuance on March 18, 2025.
Daejeon City actively promotes the 3rd D-Unicorn Project as of May 15, 2024.
TRIOAR was selected as the winner of the Seoul-BMS Innovation Square Challenge in 2023, announced on November 23, 2023.
The Small and Medium Business Administration selected 51 baby unicorn companies, providing up to 17.3 billion KRW support, announced on May 30, 2023.
TRIOAR, which possesses an ADC platform, attracted 12 billion KRW in Series A investment on May 25, 2023.
Announcement of third-party allocation of paid-in capital increase and new stock issuance on May 8, 2023.